408 related articles for article (PubMed ID: 29720577)
1. Universal monitoring of minimal residual disease in acute myeloid leukemia.
Coustan-Smith E; Song G; Shurtleff S; Yeoh AE; Chng WJ; Chen SP; Rubnitz JE; Pui CH; Downing JR; Campana D
JCI Insight; 2018 May; 3(9):. PubMed ID: 29720577
[TBL] [Abstract][Full Text] [Related]
2. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
Al-Mawali A; Pinto AD; Al-Zadjali S
Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
[TBL] [Abstract][Full Text] [Related]
4. [The immunophenotypic analysis of CD7+ and (or) CD56+ acute myeloid leukemic stem cells and its applications in minimal residual disease detection].
Cao H; Wang YZ; Wu HH; Chang Y; Hao L; Chen SS; Huang XJ; Lu DP; Liu YR
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):23-8. PubMed ID: 18512311
[TBL] [Abstract][Full Text] [Related]
5. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.
Chávez-González A; Dorantes-Acosta E; Moreno-Lorenzana D; Alvarado-Moreno A; Arriaga-Pizano L; Mayani H
Arch Med Res; 2014 May; 45(4):343-50. PubMed ID: 24751333
[TBL] [Abstract][Full Text] [Related]
7. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M
Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408
[TBL] [Abstract][Full Text] [Related]
8. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
9. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
[TBL] [Abstract][Full Text] [Related]
10. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
[TBL] [Abstract][Full Text] [Related]
12. Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes.
Camburn AE; Petrasich M; Ruskova A; Chan G
Pathology; 2019 Aug; 51(5):502-506. PubMed ID: 31262563
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
14. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact and Phenotype of Residual Acute Myeloid Leukemia Stem Cells.
Jaddaoui S; Bencharef H; Lamchahab M; Quessar A; Oukkache B
Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704721
[TBL] [Abstract][Full Text] [Related]
16. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia.
Kandeel EZ; Madney Y; Eldin DN; Shafik NF
Exp Mol Pathol; 2021 Feb; 118():104597. PubMed ID: 33358743
[TBL] [Abstract][Full Text] [Related]
18. CD34
Zeijlemaker W; Grob T; Meijer R; Hanekamp D; Kelder A; Carbaat-Ham JC; Oussoren-Brockhoff YJM; Snel AN; Veldhuizen D; Scholten WJ; Maertens J; Breems DA; Pabst T; Manz MG; van der Velden VHJ; Slomp J; Preijers F; Cloos J; van de Loosdrecht AA; Löwenberg B; Valk PJM; Jongen-Lavrencic M; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2019 May; 33(5):1102-1112. PubMed ID: 30542144
[TBL] [Abstract][Full Text] [Related]
19. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
20. CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells.
Touzet L; Dumezy F; Roumier C; Berthon C; Bories C; Quesnel B; Preudhomme C; Boyer T
Cancer Med; 2019 Mar; 8(3):1279-1288. PubMed ID: 30740913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
